News & Updates

Show Multimedia Only

Guselkumab yields durable benefit in biologic-naïve PsA patients

23 Nov 2021

The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.

Guselkumab yields durable benefit in biologic-naïve PsA patients

23 Nov 2021

Finerenone lessens HF burden among patients with CKD, diabetes

22 Nov 2021 by

Treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone helps prevent the incidence of new-onset heart failure (HF) and improve other HF outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as shown in a secondary analysis of the phase III FIGARO-DKD trial.

Finerenone lessens HF burden among patients with CKD, diabetes

22 Nov 2021

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status

22 Nov 2021 by

Data presented at AHA 2021 demonstrated the efficacy and safety of bempedoic acid for improving lipid and glycaemic parameters and hsCRP irrespective of metabolic status.

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status

22 Nov 2021

$Tocilizumab outperforms anti-TNF-α in refractory uveitic macular edema$

Tocilizumab outperforms anti-TNF-α in refractory uveitic macular edema

22 Nov 2021

Patients with refractory uveitic macular edema are more likely to achieve complete response with tocilizumab than with antitumour necrosis factor alpha (anti-TNF-α) drugs, as reported in a study.

Tocilizumab outperforms anti-TNF-α in refractory uveitic macular edema

22 Nov 2021

Colchicine cessation possible in familial Mediterranean fever with prolonged remission

21 Nov 2021

Colchicine therapy may be discontinued after prolonged remission in some children with familial Mediterranean fever (FMF), suggests a study, noting, however, that patients with arthritis or myalgia are prone to an attack following treatment cessation.

Colchicine cessation possible in familial Mediterranean fever with prolonged remission

21 Nov 2021

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

20 Nov 2021

In the treatment of patients with cirrhosis and hepatic encephalopathy (HE), the ammonia scavenger ornithine phenylacetate is safe and similar to placebo in terms of time to clinical improvement, according to data from a phase IIb trial.

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

20 Nov 2021

1-month DAPT post-PCI: Where does the limit lie?

20 Nov 2021 by

Dropping aspirin after 1 month of DAPT* with clopidogrel and aspirin following PCI** reduces major bleeding events without increasing cardiovascular (CV) events compared with continuing DAPT for 12 months, regardless of bleeding risk and complexity of PCI, according to a pooled analysis of the STOPDAPT-2 and STOPDAPT-2 ACS trials presented at TCT 2021.

1-month DAPT post-PCI: Where does the limit lie?

20 Nov 2021

How long should high-risk patients undergoing PCI receive DAPT?

20 Nov 2021

One-month treatment with dual antiplatelet therapy (DAPT) results in similar ischaemic outcomes and lower bleeding risk compared with 3 months of DAPT in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), a study has shown.

How long should high-risk patients undergoing PCI receive DAPT?

20 Nov 2021

Beta-blocker withdrawal improves functional capacity in HFpEF

20 Nov 2021

Withdrawal of beta-blocker treatment has led to increased maximal functional capacity in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence, reports a recent study, noting how use of beta-blockers deserved re-evaluation.

Beta-blocker withdrawal improves functional capacity in HFpEF

20 Nov 2021

AKI post-AMI tied to more serious kidney outcomes

19 Nov 2021 by

Patients who develop acute kidney injury (AKI) following an acute myocardial infarction (AMI) have an elevated risk of more serious kidney outcomes including persistent reductions in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), or renal death, according to results of the PARADISE-MI trial.

AKI post-AMI tied to more serious kidney outcomes

19 Nov 2021

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Guselkumab yields durable benefit in biologic-naïve PsA patients

Guselkumab yields durable benefit in biologic-naïve PsA patients

Finerenone lessens HF burden among patients with CKD, diabetes

Finerenone lessens HF burden among patients with CKD, diabetes

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status

Tocilizumab outperforms anti-TNF-α in refractory uveitic macular edema

Tocilizumab outperforms anti-TNF-α in refractory uveitic macular edema

Colchicine cessation possible in familial Mediterranean fever with prolonged remission

Colchicine cessation possible in familial Mediterranean fever with prolonged remission

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

1-month DAPT post-PCI: Where does the limit lie?

1-month DAPT post-PCI: Where does the limit lie?

How long should high-risk patients undergoing PCI receive DAPT?

How long should high-risk patients undergoing PCI receive DAPT?

Beta-blocker withdrawal improves functional capacity in HFpEF

Beta-blocker withdrawal improves functional capacity in HFpEF

AKI post-AMI tied to more serious kidney outcomes

AKI post-AMI tied to more serious kidney outcomes